These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 2862927)

  • 1. Selective interaction of novel anxiolytics with 5-hydroxytryptamine1A receptors.
    Peroutka SJ
    Biol Psychiatry; 1985 Sep; 20(9):971-9. PubMed ID: 2862927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The interoceptive discriminative stimuli induced by the novel putative anxiolytic TVX Q 7821: behavioral evidence for the specific involvement of serotonin 5-HT1A receptors.
    Spencer DG; Traber J
    Psychopharmacology (Berl); 1987; 91(1):25-9. PubMed ID: 2881318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of neuronal activity in the hippocampus by 5-hydroxytryptamine and 5-hydroxytryptamine1A selective drugs.
    Peroutka SJ; Mauk MD; Kocsis JD
    Neuropharmacology; 1987; 26(2-3):139-46. PubMed ID: 2884586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mediation of the discriminative stimulus properties of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) by the putative 5-HT1A receptor.
    Tricklebank MD; Neill J; Kidd EJ; Fozard JR
    Eur J Pharmacol; 1987 Jan; 133(1):47-56. PubMed ID: 2881789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists.
    Meller E; Goldstein M; Bohmaker K
    Mol Pharmacol; 1990 Feb; 37(2):231-7. PubMed ID: 1968223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition by 8-hydroxy-2-(di-n-propylamino) tetralin and SM-3997, a novel anxiolytic drug, of the hippocampal rhythmical slow activity mediated by 5-hydroxytryptamine1A receptors.
    Hirose A; Tsuji R; Shimizu H; Tatsuno T; Tanaka H; Kumasaka Y; Nakamura M
    Naunyn Schmiedebergs Arch Pharmacol; 1990; 341(1-2):8-13. PubMed ID: 1969119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of 5-hydroxytryptamine1a selective drugs on the 5-HT behavioral syndrome.
    Smith LM; Peroutka SJ
    Pharmacol Biochem Behav; 1986 Jun; 24(6):1513-9. PubMed ID: 2942947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavioral studies with anxiolytic drugs. IV. Serotonergic involvement in the effects of buspirone on punished behavior of pigeons.
    Witkin JM; Mansbach RS; Barrett JE; Bolger GT; Skolnick P; Weissman B
    J Pharmacol Exp Ther; 1987 Dec; 243(3):970-7. PubMed ID: 2891840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of 5-HT1A- and alpha 2-receptors in the decreased 5-hydroxytryptamine release and metabolism in rat suprachiasmatic nucleus after intravenous 8-hydroxy-2-(n-dipropylamino) tetralin.
    Marsden CA; Martin KF
    Br J Pharmacol; 1986 Oct; 89(2):277-86. PubMed ID: 2430656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the novel anxiolytics gepirone, buspirone and ipsapirone on free feeding and on feeding induced by 8-OH-DPAT.
    Gilbert F; Dourish CT
    Psychopharmacology (Berl); 1987; 93(3):349-52. PubMed ID: 2893412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective antiaggressive effects of alnespirone in resident-intruder test are mediated via 5-hydroxytryptamine1A receptors: A comparative pharmacological study with 8-hydroxy-2-dipropylaminotetralin, ipsapirone, buspirone, eltoprazine, and WAY-100635.
    de Boer SF; Lesourd M; Mocaer E; Koolhaas JM
    J Pharmacol Exp Ther; 1999 Mar; 288(3):1125-33. PubMed ID: 10027850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoradiographic localization and pharmacological characterization of [3H]tandospirone binding sites in the rat brain.
    Tanaka H; Shimizu H; Kumasaka Y; Hirose A; Tatsuno T; Nakamura M
    Brain Res; 1991 Apr; 546(2):181-9. PubMed ID: 1648988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of MDL 73005EF as a 5-HT1A selective ligand and its effects in animal models of anxiety: comparison with buspirone, 8-OH-DPAT and diazepam.
    Moser PC; Tricklebank MD; Middlemiss DN; Mir AK; Hibert MF; Fozard JR
    Br J Pharmacol; 1990 Feb; 99(2):343-9. PubMed ID: 1970269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of a 5-HT1 receptor ligand isapirone (TVX Q 7821) on 5-HT synthesis and the behavioural effects of 5-HT agonists in mice and rats.
    Goodwin GM; De Souza RJ; Green AR
    Psychopharmacology (Berl); 1986; 89(3):382-7. PubMed ID: 2941817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of 5-HT1A selective anxiolytics on lordosis behavior: interactions with progesterone.
    Mendelson SD; Gorzalka BB
    Eur J Pharmacol; 1986 Dec; 132(2-3):323-6. PubMed ID: 2880737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar pharmacological properties of 8-OH-DPAT and alnespirone (S 20499) at dopamine receptors: comparison with buspirone.
    Protais P; Lesourd M; Comoy E
    Eur J Pharmacol; 1998 Jul; 352(2-3):179-87. PubMed ID: 9716353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of potentiated startle responding in rats by 5-hydroxytryptamine1A receptor ligands.
    Mansbach RS; Geyer MA
    Eur J Pharmacol; 1988 Nov; 156(3):375-83. PubMed ID: 2975225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleotide interactions with 5-HT1A binding sites directly labeled by [3H]-8-hydroxy-2-(DI-n-propylamino)tetralin ([3H]-8-OH-DPAT).
    Schlegel JR; Peroutka SJ
    Biochem Pharmacol; 1986 Jun; 35(12):1943-9. PubMed ID: 3013203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-hydroxytryptamine (5-HT)1A receptors and the tail-flick response. I. 8-hydroxy-2-(di-n-propylamino) tetralin HBr-induced spontaneous tail-flicks in the rat as an in vivo model of 5-HT1A receptor-mediated activity.
    Millan MJ; Bervoets K; Colpaert FC
    J Pharmacol Exp Ther; 1991 Mar; 256(3):973-82. PubMed ID: 1826033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential.
    Koek W; Patoiseau JF; Assié MB; Cosi C; Kleven MS; Dupont-Passelaigue E; Carilla-Durand E; Palmier C; Valentin JP; John G; Pauwels PJ; Tarayre JP; Colpaert FC
    J Pharmacol Exp Ther; 1998 Oct; 287(1):266-83. PubMed ID: 9765347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.